In his President's Letter, Moshe Talpaz, MD, discusses all of the treatment progress made for hematologic malignancies. Belantamab mafodotin is a BCMA targeted antibody drug conjugate approved for adult patients... Noopur Raje, MD, says the future of BCMA-directed CAR T-cell therapies may lie with next-generation agents such as bb21217. Noopur Raje, MD, discusses the safety and efficacy results of the CRB-402 trial.